Stable MF-T-SPDB-DM4 Formulation Preventing Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of stable formulations for anti-mesothelin immunoconjugates like MF-T-SPDB-DM4 is challenging due to chemical and physical instability, which can lead to degradation, particle formation, and toxic side effects, making it difficult to maintain the biologically active form and ensure safety for clinical use.
Innovation Solution
A formulation comprising 5 mg/ml MF-T-SPDB-DM4, 10mM L-Histidine, 130mM Glycine, 5% sucrose, and 0.01% polysorbate 80 in a buffered aqueous solution with a pH of 5.5, which can be lyophilized and reconstituted, inhibiting aggregation and particle formation, thereby stabilizing the immunoconjugate for long-term storage and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If immunoconjugates are formulated as aqueous solutions for therapeutic use, then they can be administered directly to patients, but they suffer from chemical and physical instability leading to degradation and particle formation
Solution Approach 1:
The patent applies parameter changes by optimizing the pH of the aqueous formulation to a specific range (5.0-6.0) and adjusting excipient concentrations to achieve both direct administrability and long-term stability. The formulation uses specific concentrations of glycine (10-200 mM), histidine (5-50 mM), and sucrose (2-10%) to stabilize the immunoconjugate in liquid form without requiring lyophilization.
Solution Approach 2:
The patent creates a composite formulation system combining the immunoconjugate with multiple excipients (amino acids glycine and histidine, sugar sucrose, and surfactant polysorbate 80) that work synergistically to prevent chemical degradation and physical aggregation, enabling stable aqueous storage while maintaining therapeutic efficacy.
2Reliability
If cytotoxic drugs are conjugated to antibodies to create immunoconjugates, then therapeutic efficacy against tumor cells is improved, but chemical instability increases leading to free drug release and toxic side effects
Solution Approach 1:
The patent uses amino acid excipients (glycine and histidine) as intermediary molecules that interact with the immunoconjugate to stabilize the cytotoxic drug-linker-antibody conjugate. These intermediaries prevent premature hydrolysis of the linker bond, keeping the cytotoxic drug bound to the antibody until it reaches the target tumor cell, thereby preventing free drug release and toxic side effects.
3Duration of action of stationary object
If immunoconjugates are stored for long periods, then they remain available for therapeutic use, but aggregation and particle formation occur reducing potency and increasing immunogenicity
Solution Approach 1:
The patent applies beforehand cushioning by incorporating protective excipients (sucrose as a stabilizer and polysorbate 80 as a surfactant) into the formulation before storage. These excipients create a protective environment that cushions the immunoconjugate against aggregation and particle formation during long-term storage, maintaining monomeric form and preventing immunogenicity.
Solution Approach 2:
The patent stabilizes the immunoconjugate during long-term storage by controlling physical-chemical parameters including pH (5.0-6.0), ionic strength (through glycine and histidine concentrations), and molecular crowding (through sucrose concentration). These parameter optimizations prevent aggregation pathways while maintaining solubility and therapeutic activity over extended storage periods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed formulation provides a stable, long-lasting solution that prevents high molecular weight aggregate formation and chemical instability, ensuring the immunoconjugate remains effective and safe for up to 1 to 5 years, reducing the risk of toxic side effects and maintaining therapeutic efficacy.
Implementation Method 1
a buffered aqueous solution having a pH of 5.5
Implementation Method 2
5% sucrose
Implementation Method 3
0.01% polysorbate 80
Implementation Method 4
The described stable aqueous formulation comprising MF-T-SPDB-DM4 is directly suitable for therapeutic applications and for subsequent lyophilization
Data Source
AI summary
The present invention relates to a stable formulation particularly suitable for the anti-mesothelin immunoconjugate MF-T-SPDB-DM4. The described stable aqueous formulation comprising MF-T-SPDB-DM4 is directly suitable for therapeutic applications and for subsequent lyophilization. The lyophilized powder can be reconstituted with water to create a reconstituted solution which is again suitable for therapeutic applications. It is a further object to provide a stable reconstituted protein formulation which is suitable for therapeutic administrations.